Stress cardiomyopathy secondary prevention: Difference between revisions
Dima Nimri (talk | contribs) |
Dima Nimri (talk | contribs) |
||
Line 7: | Line 7: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Stress cardiomyopathy is a self-limiting disease, which usually resolves within a few weeks. However, medical therapy may be necessary during the acute phase of the illness or when complications arise. | Stress cardiomyopathy is a self-limiting disease, which usually resolves within a few weeks. However, medical therapy may be necessary during the acute phase of the illness or when complications arise.<ref name="pmid27538839">{{cite journal |vauthors=Brunetti ND, Santoro F, De Gennaro L, Correale M, Kentaro H, Gaglione A, Di Biase M |title=Therapy of stress (takotsubo) cardiomyopathy: present shortcomings and future perspectives |journal=Future Cardiol |volume=12 |issue=5 |pages=563–72 |year=2016 |pmid=27538839 |doi=10.2217/fca-2016-0014 |url=}}</ref> | ||
==References== | ==References== |
Revision as of 21:28, 9 January 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Stress cardiomyopathy Microchapters |
Diagnosis |
---|
Treatment |
Unstable angina/non ST elevation myocardial infarction in Stress (Takotsubo) Cardiomyopathy |
Case Studies |
Stress cardiomyopathy secondary prevention On the Web |
American Roentgen Ray Society Images of Stress cardiomyopathy secondary prevention |
Risk calculators and risk factors for Stress cardiomyopathy secondary prevention |
Overview
Stress cardiomyopathy is a self-limiting disease, which usually resolves within a few weeks. However, medical therapy may be necessary during the acute phase of the illness or when complications arise.
Secondary Prevention
Stress cardiomyopathy is a self-limiting disease, which usually resolves within a few weeks. However, medical therapy may be necessary during the acute phase of the illness or when complications arise.[1]
References
- ↑ Brunetti ND, Santoro F, De Gennaro L, Correale M, Kentaro H, Gaglione A, Di Biase M (2016). "Therapy of stress (takotsubo) cardiomyopathy: present shortcomings and future perspectives". Future Cardiol. 12 (5): 563–72. doi:10.2217/fca-2016-0014. PMID 27538839.